40 completed, 9 terminated, 6 unknown, 3 recruiting. 61 Phase 2, 13 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 61 | Completed 40, Terminated 9, Unknown 6, Recruiting 3, Withdrawn 3 |
| Phase 3 | 13 | Completed 7, Unknown 4, Terminated 2 |
| Phase 1 | 6 | Completed 3, Recruiting 2, Terminated 1 |
Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) Lopinavir / ritonavir - Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection | Phase 2 | Recruiting | Daré Bioscience, Inc. | 118 | 2026-07-17 | 2026-11-06 |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 862 | 2023-08-17 | 2026-10-21 |
| Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2021-05-01 | 2021-04-26 | |
| Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 294 | 2020-11-27 | 2024-12-27 |
| FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals Favipiravir, Lopinavir/ Ritonavir, Favipiravir Placebo - COVID-19 | Phase 2 | Completed | University College, London | 240 | 2020-09-24 | 2022-12-15 |
| the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19 | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 100 | 2020-08-20 | 2020-08-20 |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Lopinavir/Ritonavir 400 mg/100 mg, Placebo - COVID-19 | Phase 2 | Completed | Vanderbilt University Medical Center | 452 | 2020-06-01 | 2024-02-28 |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Baricitinib - Pharmacological Action | Phase 2 / Phase 3 | Unknown | Hospital of Prato | 200 | 2020-05-16 | 2020-04-22 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 Favipiravir, Standard of Care - COVID-19 | Phase 2 / Phase 3 | Unknown | Chromis LLC | 330 | 2020-04-23 | 2020-06-16 |
| Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19 | Phase 2 / Phase 3 | Unknown | Medical University of Vienna | 500 | 2020-04-16 | 2021-03-02 |
| Treatment for COVID-19 in High-Risk Adult Outpatients Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Terminated | University of Washington | 289 | 2020-04-16 | 2022-08-08 |
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 60 | 2020-04-09 | 2020-05-05 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine - COVID-19 | Phase 2 / Phase 3 | Unknown | Fasa University of Medical Sciences | 30 | 2020-04-04 | 2020-04-13 |
| Baricitinib Therapy in COVID-19 Baricitinib 4 MG Oral Tablet - COVID, Pneumonia | Phase 2 / Phase 3 | Completed | Fabrizio Cantini | 12 | 2020-03-16 | 2020-04-24 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) Lopinavir/ritonavir, Hydroxychloroquine sulfate - COVID-19 | Phase 2 | Terminated | Asan Medical Center | 65 | 2020-03-11 | 2020-05-27 |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B - Novel Coronavirus Infection | Phase 2 | Completed | The University of Hong Kong | 127 | 2020-02-10 | 2020-04-15 |
| Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) - Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Terminated | BioXcellerator | 6 | 2020-01-13 | 2024-08-27 |
| First-Line Treatment for HIV-2 Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir - HIV-2 Infection | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 210 | 2016-01-26 | 2019-07-22 |
| Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Raltegravir, Lopinavir/Ritonavir - HIV, Pregnancy | Phase 2 / Phase 3 | Terminated | Fundação Bahiana de Infectologia | 33 | 2015-06-01 | 2024-10-15 |
Showing 20 of 61. Sign in to see all of them.
HIV Infections (34) · COVID-19 (13) · Coronavirus Infections (3) · Infections (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis C (2) · Tuberculosis (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Coinfection (1) · Directly Observed Therapy (1) · Disease Progression (1) · Ependymoma (1)
National Institute of Allergy and Infectious Diseases (NIAID) (13) · Abbott (5) · ANRS, Emerging Infectious Diseases (3) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3) · The HIV Netherlands Australia Thailand Research Collaboration (3) · ViiV Healthcare (3) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Shahid Beheshti University of Medical Sciences (2) · Asan Medical Center (1) · BioXcellerator (1) · Boehringer Ingelheim (1) · Case Comprehensive Cancer Center (1) · Chromis LLC (1) · Daré Bioscience, Inc. (1) · DualityBio Inc. (1)
United States (29) · South Africa (8) · Puerto Rico (7) · Thailand (6) · Canada (5) · Brazil (4) · France (4) · Italy (4) · Malawi (4) · Uganda (4) · Argentina (3) · Germany (3) · Haiti (3) · Kenya (3) · Tanzania (3)
Kiat Ruxrungtham, MD (2) · Alfredo Hernandez-Ruiz, MSc (1) · Andrea Thurman, MD (1) · Andrew Wiznia, MD (1) · Ann J. Melvin, MD, MPH (1) · Anthony D Harries, MD, PhD (1) · Avy Violari, MD (1) · Barbara A da Silva, M.D. (1) · Barbara da Silva, M.D. (1) · Behnam Rahimi, M.D (1) · Bernd Jilma, MD (1) · Carlos Brites, MD, PhD (1) · Charles Flexner, MD (1)
PMID 34473343, PMID 16962381, PMID 18540803, PMID 18625762, PMID 18647794, PMID 19008157, PMID 19237646, PMID 19512937, PMID 19597072, PMID 19729375, PMID 20192725, PMID 20554983, PMID 20842042, PMID 20942667, PMID 21124227, PMID 21266910, PMID 22144539, PMID 22180621, PMID 22293065, PMID 22716976, PMID 23300238, PMID 23766338, PMID 24086319, PMID 24180000, PMID 25037041, PMID 25222305, PMID 25406657, PMID 25838291, PMID 26482301, PMID 26684818, PMID 26977746, PMID 27439527, PMID 27516476, PMID 29189677, PMID 29767684, PMID 30102656, PMID 30968368, PMID 32321635, PMID 32401715, PMID 32493468, PMID 32555385, PMID 32618282, PMID 32738928, PMID 32770240, PMID 33106183, PMID 33681731, PMID 33685502, PMID 33850184, PMID 34224994, PMID 34693933
U01AI068636 (3), 2009 (1), U01AI064002 (1), U01AI068632 (1), UM1AI068616 (1), UM1AI068632 (1), UM1AI106716 (1)